1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amgen, J&J Myasthenia Gravis Data Show Potential Market Opportunities

 
• By Alaric DeArment

The companies presented data for Uplizna and nipocalimab in gMG at a medical meeting. J&J’s nipocalimab is pending for approval in the disease, while Amgen is working on submitting Uplizna.

Concept of Myasthenia Gravis written on sticky notes isolated on Wooden Table.
Amgen and J&J presented data in generalized myasthenia gravis at the AANEM meeting • Source: Shutterstock

Amgen Inc. has what might be – at least by one analyst’s estimates – a blockbuster opportunity for the approved drug Uplizna (inebilizumab-cdon), while Johnson & Johnson stands to expand the potential market for its Phase III drug nipocalimab, which it has submitted to regulators for review, in generalized myasthenia gravis (gMG).

Key Takeaways
  • Amgen presented Phase III data for Uplizna in gMG among adults, while J&J presented Phase II/III data among adolescents for nipocalimab, with both drugs showing good efficacy.
  • The adolescent population represents a small subset of gMG overall, but it’s part of a potential multibillion-dollar opportunity for J&J’s drug

Amgen presented data from the Phase III MINT trial of Uplizna in adults on 15 October at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting in Savannah, GA

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

More from Therapy Areas

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.